Gene

FNTB

farnesyltransferase, CAAX box, subunit beta

Explore in graph →CI-GENE-00002109HGNC:3785 ENSG00000257365 NCBI 2342 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FNTB RS116238661
Lonafarnib	Malignant Ovarian Neoplasm	Predictive	B	Supports Resistance	2	accepted	EID815 57 from 105 patients in the AGo-OVAR-15 trial were retrospectively genotyped for FNTB polymorphisms. Resistance to lonafarnib-containing treatment was limited to patients with a FNTB rs11623866 (c.-60… (full text at CIViC) PMID 26033044 · Bachmann et al., 2015 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (1)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved1 cohort row · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Cholangiocarcinoma (National Cancer Centre of Singapore, Nat Genet 2013) chol_nccs_2013	Cholangiocarcinoma	Ssm	1

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.
· Br J Clin Pharmacol · 2015 · PMID 26033044 · validated civic_curation pubmed